Jeffrey P Krischer1. 1. Division of Informatics and Biostatistics, Department of Pediatrics, University of South Florida, Tampa, FL 33612, USA. jpkrischer@epi.usf.edu
Abstract
AIMS/HYPOTHESIS: This paper presents a rationale for the selection of intermediate endpoints to be used in the design of type 1 diabetes prevention clinical trials. METHODS: Relatives of individuals diagnosed with type 1 diabetes were enrolled on the TrialNet Natural History Study and screened for diabetes-related autoantibodies. Those with two or more such autoantibodies were analysed with respect to increased HbA1c, decreased C-peptide following an OGTT, or abnormal OGTT values as intermediate markers of disease progression. RESULTS: Over 2 years, a 10% increase in HbA1c, and a 20% or 30% decrease in C-peptide from baseline, or progression to abnormal OGTT, occurred with a frequency between 20% and 41%. The 3- to 5-year risk of type 1 diabetes following each intermediate endpoint was high, namely 47% to 84%. The lower the incidence of the endpoint being reached, the higher the risk of diabetes. A diabetes prevention trial using these intermediate endpoints would require a 30% to 50% smaller sample size than one using type 1 diabetes as the endpoint. CONCLUSIONS/ INTERPRETATION: The use of an intermediate endpoint in diabetes prevention is based on the generally held view of disease progression from initial occurrence of autoantibodies through successive immunological and metabolic changes to manifest type 1 diabetes. Thus, these markers are suitable for randomised phase 2 trials, which can more rapidly screen promising new therapies, allowing them to be subsequently confirmed in definitive phase 3 trials.
AIMS/HYPOTHESIS: This paper presents a rationale for the selection of intermediate endpoints to be used in the design of type 1 diabetes prevention clinical trials. METHODS: Relatives of individuals diagnosed with type 1 diabetes were enrolled on the TrialNet Natural History Study and screened for diabetes-related autoantibodies. Those with two or more such autoantibodies were analysed with respect to increased HbA1c, decreased C-peptide following an OGTT, or abnormal OGTT values as intermediate markers of disease progression. RESULTS: Over 2 years, a 10% increase in HbA1c, and a 20% or 30% decrease in C-peptide from baseline, or progression to abnormal OGTT, occurred with a frequency between 20% and 41%. The 3- to 5-year risk of type 1 diabetes following each intermediate endpoint was high, namely 47% to 84%. The lower the incidence of the endpoint being reached, the higher the risk of diabetes. A diabetes prevention trial using these intermediate endpoints would require a 30% to 50% smaller sample size than one using type 1 diabetes as the endpoint. CONCLUSIONS/ INTERPRETATION: The use of an intermediate endpoint in diabetes prevention is based on the generally held view of disease progression from initial occurrence of autoantibodies through successive immunological and metabolic changes to manifest type 1 diabetes. Thus, these markers are suitable for randomised phase 2 trials, which can more rapidly screen promising new therapies, allowing them to be subsequently confirmed in definitive phase 3 trials.
Authors: Jeffrey L Mahon; Jay M Sosenko; Lisa Rafkin-Mervis; Heidi Krause-Steinrauf; John M Lachin; Clinton Thompson; Polly J Bingley; Ezio Bonifacio; Jerry P Palmer; George S Eisenbarth; Joseph Wolfsdorf; Jay S Skyler Journal: Pediatr Diabetes Date: 2008-09-24 Impact factor: 4.866
Authors: Jay M Sosenko; Jerry P Palmer; Carla J Greenbaum; Jeffrey Mahon; Catherine Cowie; Jeffrey P Krischer; H Peter Chase; Neil H White; Bruce Buckingham; Kevan C Herold; David Cuthbertson; Jay S Skyler Journal: Diabetes Care Date: 2006-03 Impact factor: 19.112
Authors: Jay S Skyler; Jeffrey P Krischer; Joseph Wolfsdorf; Catherine Cowie; Jerry P Palmer; Carla Greenbaum; David Cuthbertson; Lisa E Rafkin-Mervis; H Peter Chase; Ellen Leschek Journal: Diabetes Care Date: 2005-05 Impact factor: 19.112
Authors: Jay M Sosenko; Jerry P Palmer; Lisa Rafkin-Mervis; Jeffrey P Krischer; David Cuthbertson; Della Matheson; Jay S Skyler Journal: Diabetes Care Date: 2008-07-23 Impact factor: 17.152
Authors: Jay M Sosenko; Jay S Skyler; Craig A Beam; David Boulware; Jeffrey L Mahon; Jeffrey P Krischer; Carla J Greenbaum; Lisa E Rafkin; Della Matheson; Kevan C Herold; Jerry P Palmer Journal: Diabetes Care Date: 2015-03-10 Impact factor: 19.112
Authors: Andrea K Steck; Fran Dong; Iman Taki; Michelle Hoffman; Kimber Simmons; Brigitte I Frohnert; Marian J Rewers Journal: J Clin Endocrinol Metab Date: 2019-08-01 Impact factor: 5.958
Authors: Annelien Van Dalem; Simke Demeester; Eric V Balti; Katelijn Decochez; Ilse Weets; Evy Vandemeulebroucke; Ursule Van de Velde; An Walgraeve; Nicole Seret; Christophe De Block; Johannes Ruige; Pieter Gillard; Bart Keymeulen; Daniel G Pipeleers; Frans K Gorus Journal: Diabetologia Date: 2015-09-26 Impact factor: 10.122
Authors: Brandon M Nathan; Maria J Redondo; Heba Ismail; Laura Jacobsen; Emily K Sims; Jerry Palmer; Jay Skyler; Laura Bocchino; Susan Geyer; Jay M Sosenko Journal: Diabetes Care Date: 2022-02-01 Impact factor: 19.112
Authors: Wendy K Chung; Karel Erion; Jose C Florez; Andrew T Hattersley; Marie-France Hivert; Christine G Lee; Mark I McCarthy; John J Nolan; Jill M Norris; Ewan R Pearson; Louis Philipson; Allison T McElvaine; William T Cefalu; Stephen S Rich; Paul W Franks Journal: Diabetologia Date: 2020-09 Impact factor: 10.122